OTCMKTS:DCHPF Dechra Pharmaceuticals (DCHPF) Stock Price, News & Analysis $46.90 0.00 (0.00%) As of 01/18/2024 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Dechra Pharmaceuticals Stock (OTCMKTS:DCHPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dechra Pharmaceuticals alerts:Sign Up Key Stats Today's Range$46.90▼$46.9050-Day Range$46.90▼$46.9052-Week Range$30.00▼$47.40VolumeN/AAverage Volume1,687 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Dechra Pharmaceuticals plc is a UK-based global specialist in veterinary pharmaceuticals, trading on the London Stock Exchange and quoted in the United States on the OTC market under the symbol DCHPF. Founded in 1997 and headquartered in Northwich, Cheshire, the company focuses exclusively on the development, manufacture and marketing of products for veterinary use. Dechra serves both companion and food-producing animal markets through a portfolio of branded pharmaceuticals and specialty compounds. The company’s product range spans key therapeutic areas including endocrinology, dermatology, ophthalmology, pain management and anti-infectives. Dechra develops and commercializes oral and injectable pharmaceuticals, topical formulations and vaccines, as well as ancillary products such as anaesthetics and nutritional supplements. Research and development efforts emphasize innovative therapies with a high degree of formulation expertise, supported by in-house manufacturing and quality control capabilities across multiple sites. Dechra maintains a presence in more than 50 countries, operating through regional sales and distribution networks in Europe, North America, Australasia and selected emerging markets. The company has grown organically and by targeted acquisitions, bringing niche veterinary assets into its platform to enhance its specialty focus. Leadership is headed by Chief Executive Officer Bill Siggers, under whom Dechra continues to pursue a strategy of narrow-area expertise and tailored geographic expansion.AI Generated. May Contain Errors. Read More Receive DCHPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCHPF Stock News HeadlinesDechra Pharmaceuticals PLC (LON:DPH) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?May 13, 2022 | finance.yahoo.comFTSE 100 firms hit boardroom diversity targets but fail at executive levelMarch 16, 2022 | uk.finance.yahoo.comForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.September 14 at 2:00 AM | Banyan Hill Publishing (Ad)Anivive Licenses Novel Canine Cancer Therapeutic to Expand Sales and Accelerate PipelineJanuary 12, 2022 | prnewswire.comDechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29September 14, 2021 | finance.yahoo.comGoldman Sachs picks London for private-equity IPO as FTSE climbs after U.S. jobs dataSeptember 6, 2021 | finance.yahoo.comCalculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)August 7, 2021 | finance.yahoo.comSee More Headlines DCHPF Stock Analysis - Frequently Asked Questions How have DCHPF shares performed this year? Dechra Pharmaceuticals' stock was trading at $46.90 at the beginning of the year. Since then, DCHPF stock has increased by 0.0% and is now trading at $46.90. How do I buy shares of Dechra Pharmaceuticals? Shares of DCHPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryPersonal Services Current SymbolOTCMKTS:DCHPF CIKN/A Webdechra.com Phone441606814730FaxN/AEmployees2,457Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:DCHPF) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dechra Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Dechra Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.